Intravenous immunoglobulin therapy for children with Stevens-Johnson syndrome

M. V. Morici, W. K. Galen, A. K. Shetty, R. P. Lebouef, T. P. Gouri, G. S. Cowan, A. Gedalia

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

Objective. To review the experience with intravenous immunoglobulin (IVIG) therapy in patients with Stevens-Johnson syndrome (SJS) in our institution. Methods. All charts of patients with SJS admitted to Children's Hospital between November 1988 and June 1998 were reviewed. Results. Twelve patients with SJS were detected. There were 8 males and 4 females, with a mean age 6 years (range 10 mo to 17 yrs). All patients presented with high fever and cutaneous and mucous membrane changes, and the diagnosis SJS was confirmed by a dermatologist. Of the 12 patients with SJS, 7 were treated with IVIG, 2 with corticosteroids, and 3 with supportive care. IVIG was administered in a single infusion at 1.5-2 g/kg, and was given on an average of hospital day 3 (range 1-8 days). The average duration of fever was 8 days (range 3-14) in the IVIG treated patients compared to 14 days (range 6-20) in the non-IVIG treated group (p = 0.06). The mean hospital stay was 12 days (range 4-22) for the patients treated with IVIG and 15 days (range 6-25) for the non-IVIG treated group (p = 0.5). No toxicity was observed with IVIG therapy. Conclusion. Duration of fever was shortened in patients treated with IVIG, although statistical significance was marginal. The hospital stay was slightly shortened in patients treated with IVIG; however, statistical significance was not reached. Prospective and controlled, multicenter studies are needed to further investigate these preliminary findings.

Original languageEnglish
Pages (from-to)2494-2497
Number of pages4
JournalJournal of Rheumatology
Volume27
Issue number10
Publication statusPublished - 01-01-2000
Externally publishedYes

Fingerprint

Stevens-Johnson Syndrome
Passive Immunization
Intravenous Immunoglobulins
Fever
Immunoglobulins
Length of Stay
Multicenter Studies
Adrenal Cortex Hormones
Mucous Membrane
Skin

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Rheumatology
  • Immunology

Cite this

Morici, M. V., Galen, W. K., Shetty, A. K., Lebouef, R. P., Gouri, T. P., Cowan, G. S., & Gedalia, A. (2000). Intravenous immunoglobulin therapy for children with Stevens-Johnson syndrome. Journal of Rheumatology, 27(10), 2494-2497.
Morici, M. V. ; Galen, W. K. ; Shetty, A. K. ; Lebouef, R. P. ; Gouri, T. P. ; Cowan, G. S. ; Gedalia, A. / Intravenous immunoglobulin therapy for children with Stevens-Johnson syndrome. In: Journal of Rheumatology. 2000 ; Vol. 27, No. 10. pp. 2494-2497.
@article{6ec9fcada2254c04a57a9fa3d2921964,
title = "Intravenous immunoglobulin therapy for children with Stevens-Johnson syndrome",
abstract = "Objective. To review the experience with intravenous immunoglobulin (IVIG) therapy in patients with Stevens-Johnson syndrome (SJS) in our institution. Methods. All charts of patients with SJS admitted to Children's Hospital between November 1988 and June 1998 were reviewed. Results. Twelve patients with SJS were detected. There were 8 males and 4 females, with a mean age 6 years (range 10 mo to 17 yrs). All patients presented with high fever and cutaneous and mucous membrane changes, and the diagnosis SJS was confirmed by a dermatologist. Of the 12 patients with SJS, 7 were treated with IVIG, 2 with corticosteroids, and 3 with supportive care. IVIG was administered in a single infusion at 1.5-2 g/kg, and was given on an average of hospital day 3 (range 1-8 days). The average duration of fever was 8 days (range 3-14) in the IVIG treated patients compared to 14 days (range 6-20) in the non-IVIG treated group (p = 0.06). The mean hospital stay was 12 days (range 4-22) for the patients treated with IVIG and 15 days (range 6-25) for the non-IVIG treated group (p = 0.5). No toxicity was observed with IVIG therapy. Conclusion. Duration of fever was shortened in patients treated with IVIG, although statistical significance was marginal. The hospital stay was slightly shortened in patients treated with IVIG; however, statistical significance was not reached. Prospective and controlled, multicenter studies are needed to further investigate these preliminary findings.",
author = "Morici, {M. V.} and Galen, {W. K.} and Shetty, {A. K.} and Lebouef, {R. P.} and Gouri, {T. P.} and Cowan, {G. S.} and A. Gedalia",
year = "2000",
month = "1",
day = "1",
language = "English",
volume = "27",
pages = "2494--2497",
journal = "Journal of Rheumatology",
issn = "0315-162X",
publisher = "Journal of Rheumatology",
number = "10",

}

Morici, MV, Galen, WK, Shetty, AK, Lebouef, RP, Gouri, TP, Cowan, GS & Gedalia, A 2000, 'Intravenous immunoglobulin therapy for children with Stevens-Johnson syndrome', Journal of Rheumatology, vol. 27, no. 10, pp. 2494-2497.

Intravenous immunoglobulin therapy for children with Stevens-Johnson syndrome. / Morici, M. V.; Galen, W. K.; Shetty, A. K.; Lebouef, R. P.; Gouri, T. P.; Cowan, G. S.; Gedalia, A.

In: Journal of Rheumatology, Vol. 27, No. 10, 01.01.2000, p. 2494-2497.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Intravenous immunoglobulin therapy for children with Stevens-Johnson syndrome

AU - Morici, M. V.

AU - Galen, W. K.

AU - Shetty, A. K.

AU - Lebouef, R. P.

AU - Gouri, T. P.

AU - Cowan, G. S.

AU - Gedalia, A.

PY - 2000/1/1

Y1 - 2000/1/1

N2 - Objective. To review the experience with intravenous immunoglobulin (IVIG) therapy in patients with Stevens-Johnson syndrome (SJS) in our institution. Methods. All charts of patients with SJS admitted to Children's Hospital between November 1988 and June 1998 were reviewed. Results. Twelve patients with SJS were detected. There were 8 males and 4 females, with a mean age 6 years (range 10 mo to 17 yrs). All patients presented with high fever and cutaneous and mucous membrane changes, and the diagnosis SJS was confirmed by a dermatologist. Of the 12 patients with SJS, 7 were treated with IVIG, 2 with corticosteroids, and 3 with supportive care. IVIG was administered in a single infusion at 1.5-2 g/kg, and was given on an average of hospital day 3 (range 1-8 days). The average duration of fever was 8 days (range 3-14) in the IVIG treated patients compared to 14 days (range 6-20) in the non-IVIG treated group (p = 0.06). The mean hospital stay was 12 days (range 4-22) for the patients treated with IVIG and 15 days (range 6-25) for the non-IVIG treated group (p = 0.5). No toxicity was observed with IVIG therapy. Conclusion. Duration of fever was shortened in patients treated with IVIG, although statistical significance was marginal. The hospital stay was slightly shortened in patients treated with IVIG; however, statistical significance was not reached. Prospective and controlled, multicenter studies are needed to further investigate these preliminary findings.

AB - Objective. To review the experience with intravenous immunoglobulin (IVIG) therapy in patients with Stevens-Johnson syndrome (SJS) in our institution. Methods. All charts of patients with SJS admitted to Children's Hospital between November 1988 and June 1998 were reviewed. Results. Twelve patients with SJS were detected. There were 8 males and 4 females, with a mean age 6 years (range 10 mo to 17 yrs). All patients presented with high fever and cutaneous and mucous membrane changes, and the diagnosis SJS was confirmed by a dermatologist. Of the 12 patients with SJS, 7 were treated with IVIG, 2 with corticosteroids, and 3 with supportive care. IVIG was administered in a single infusion at 1.5-2 g/kg, and was given on an average of hospital day 3 (range 1-8 days). The average duration of fever was 8 days (range 3-14) in the IVIG treated patients compared to 14 days (range 6-20) in the non-IVIG treated group (p = 0.06). The mean hospital stay was 12 days (range 4-22) for the patients treated with IVIG and 15 days (range 6-25) for the non-IVIG treated group (p = 0.5). No toxicity was observed with IVIG therapy. Conclusion. Duration of fever was shortened in patients treated with IVIG, although statistical significance was marginal. The hospital stay was slightly shortened in patients treated with IVIG; however, statistical significance was not reached. Prospective and controlled, multicenter studies are needed to further investigate these preliminary findings.

UR - http://www.scopus.com/inward/record.url?scp=0033789635&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033789635&partnerID=8YFLogxK

M3 - Article

VL - 27

SP - 2494

EP - 2497

JO - Journal of Rheumatology

JF - Journal of Rheumatology

SN - 0315-162X

IS - 10

ER -

Morici MV, Galen WK, Shetty AK, Lebouef RP, Gouri TP, Cowan GS et al. Intravenous immunoglobulin therapy for children with Stevens-Johnson syndrome. Journal of Rheumatology. 2000 Jan 1;27(10):2494-2497.